title: [New treatments for hepatitis C, which targets, what timeline?].
abstract: The hepatitis C virus (HCV) is a global major health burden, its response to current treatment is unfortunately inadequate, in particular for genotype 1. Two new direct acting antivirals, that inhibit NS3/4A viral protease, will soon be available on the Swiss market: telaprevir and boceprevir. These substances increase the rate of sustained viral response, in HCV genotype 1 infected patients, when coadministered with pegylated interferon and ribavirin. However, these new molecules may lead to serious adverse effects and drug interactions with which the specialist and the primary care physician must be familiar.
authors: Service de gastroentérologie et d'hépatologie, Département des spécialités, HUG, 1211 Genève 14. nicolas.goossens@hcuge.ch
authors: Nicolas
authors: N
authors: Goossens
authors: Francesco
authors: F
authors: Negro
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline